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Females with germline mutations in BRCA1
are predisposed to develop breast and ovar-
ian cancers. A previous report indicated that
BRCA1 colocalizes with and is necessary for
the correct localization of XIST, a noncoding
RNA that coats the inactive X chromosome (Xi)
to mediate formation of facultative heterochro-
matin. A model emerged from this study sug-
gesting that loss of BRCA1 in female cells could
reactivate genes on the Xi through loss of
the XIST RNA. However, our independent stud-
ies of BRCA1 and XIST RNA revealed little
evidence to support this model. We report that
BRCA1 is not enriched on XIST RNA-coated
chromatin of the Xi. Neither mutation nor deple-
tion of BRCA1 causes significant changes in
XIST RNA localization or X-linked gene expres-
sion. Together, these results do not support
a role for BRCA1 in promoting XIST RNA locali-
zation to the Xi or regulating XIST-dependent
functions in maintaining the stability of faculta-
tive heterochromatin.
INTRODUCTION
Mutations in breast cancer-associated gene 1 (BRCA1)
are associated with hereditary breast and ovarian cancers
(Alberg et al., 1999; Brody and Biesecker, 1998). BRCA1
encodes a ubiquitin ligase that acts in checkpoint andDNA damage-repair pathways to ensure genome integrity
(Deng, 2006; Venkitaraman, 2002). In addition, BRCA1
plays a role in meiotic XY inactivation (Turner et al.,
2004). BRCA1 has also been implicated in regulation of
somatic cell X inactivation, leading to the suggestion
that loss of BRCA1 in female cells may lead to Xi perturba-
tion and destabilization of its silenced state (Ganesan
et al., 2002). This finding has impacted both the breast
cancer and X inactivation research communities.
In female mammals, one X chromosome is silenced in
each cell to achieve equivalent X-linked gene dosage be-
tween females and males. X inactivation occurs early in
mammalian embryogenesis, and in the mouse, the Xist
gene is essential for the initiation of X chromosome silenc-
ing (Marahrens et al., 1997; Penny et al., 1996). When X in-
activation is initiated, Xist RNA spreads from its site of
transcription to coat the X chromosome, and this cis-
spread correlates with the initial transcriptional silencing
of the Xi (Panning et al., 1997; Sheardown et al., 1997).
During the maintenance phase of X inactivation, an accu-
mulation of XIST RNA coats the Xi in somatic cells (Brown
et al., 1992). Deletion of the XIST/Xist gene in somatic cells
does not result in complete reactivation of the Xi (Brown
andWillard, 1994; Csankovszki et al., 2001). Instead, there
is stochastic and infrequent gene reactivation, indicating
that Xist acts with other factors to maintain silencing of
the Xi (Csankovszki et al., 2001).
Ganesan et al. (2002) presented several lines of evi-
dence implicating BRCA1 in regulation of X inactivation.
First, BRCA1 was enriched with the XIST RNA-coated
chromatin of the Xi in female cells. Second, localized
XIST RNA was not detected in BRCA1 mutant tumors
and cell lines. Third, when wild-type BRCA1 was used toCell 128, 977–989, March 9, 2007 ª2007 Elsevier Inc. 977
reconstitute a BRCA1-deficient cell line, XIST RNA was
detected in a pattern consistent with its association with
an Xi chromosome. Fourth, XIST RNA was no longer de-
tected on the Xi when BRCA1 was depleted by RNA inter-
ference (RNAi). Fifth, while XIST RNA was not detected in
BRCA1/ tumors, it was correctly localized in BRCA1-
positive sporadic breast cancer samples. Finally, knock-
down of BRCA1 activated expression of an Xi-linked
GFP, consistent with a role in maintaining X inactivation.
Together, these results suggested that BRCA1 contrib-
utes to the stable silencing of X-linked genes by regulating
the localization of XIST RNA. These findings were signifi-
cant because BRCA1 was the first factor implicated as
playing a role in XIST RNA localization and because they
provided a possible mechanism by which loss of BRCA1
could contribute to cancer progression.
However, our independent studies to extend the find-
ings of Ganesan et al. (2002) indicate that BRCA1 does
not regulate XIST RNA. We report that BRCA1 does not
colocalize with XIST RNA in any cell type assayed. Recon-
stitution of BRCA1 in BRCA1mutant cell lines does not af-
fect XIST RNA distribution. Depletion of BRCA1 in wild-
type cells does not alter XIST RNA localization. In mouse
tumor cells mutant for Brca1, Xist RNA exhibits a normal
distribution in 11 of 14 primary tumor lines. A human
breast cancer cell line expressing mutant BRCA1 also
shows normal XIST RNA distribution in the majority of
cells. Finally, dosage compensation in mouse Brca1 mu-
tant embryos and adult mammary tissues is normal. In
combination, these results do not support a role for
BRCA1 in regulation of XIST RNA localization or its func-
tion in X inactivation.
RESULTS
Localization of BRCA1 Relative to the Xi
BRCA1 was previously reported to colocalize with XIST
RNA on the Xi in several different human female somatic
cell types (Ganesan et al., 2002). However, only a subset
of cells in asynchronous populations displayed near per-
fect overlap of BRCA1 and XIST (5%–10%), suggesting
that BRCA1 recruitment to the Xi may be transient. We
tested whether the frequency of BRCA1 association with
the Xi might differ in cell populations initiating X inactiva-
tion versus cells in the maintenance phase of X inactiva-
tion. However, when we examined cells in the earliest
stages of X inactivation and two terminally differentiated
cell types, we did not detect significant overlap between
BRCA1 and the Xi in any developmental context (see
Figure S1 in the Supplemental Data available with this
article online).
These data prompted us to characterize localization of
BRCA1 in the human cell types that were reported to
show BRCA1/XIST RNA colocalization (HMEC-t, IMR-
90, and WI-38), using the same monoclonal antibodies
and fixation conditions (Experimental Procedures;
Ganesan et al., 2002). Consistent with previous studies
of human somatic cell Xi structure, the histone variant978 Cell 128, 977–989, March 9, 2007 ª2007 Elsevier Inc.macroH2A1 and XISTRNA showed significant overlap co-
incident with the Barr body (Figure 1A; Clemson et al.,
1996; Costanzi and Pehrson, 1998). In contrast, when
we compared BRCA1 localization relative to XIST RNA,
we observed three general patterns of localization in all
cell lines and with all antibodies tested, none of which
were consistent with BRCA1 ‘‘coating’’ the XIST RNA-en-
riched component of the Xi (Figures 1B–1D; Figure S2; Ta-
ble S1). For example, in WI-38 cells, the vast majority
(98%) of cells staining positive for BRCA1 showed small
discrete foci distributed throughout the nucleus (Scully
et al., 1997a, 1997b), with no apparent spatial relationship
with the Xi (Figure 1B; Table S1). In a small percentage
(1.9%) of cells, one small BRCA1 nuclear focus appeared
closely apposed to theXISTRNA signal yet did not overlap
with the XIST RNA (Figure 1C). Only in rare cases did
BRCA1 display a patchy appearance near XIST RNA
(<0.1%; Figures 1D and 1E); however, even in these
events, BRCA1 still appeared to be largely nonoverlapping
with the XIST RNA signal. In sum, BRCA1 abutted XIST
RNA or showed only minimal overlap in <3% of cells in
all cell types examined. Whereas Ganesan et al. reported
a 5%–10% frequency of significant BRCA1/XIST RNA
overlap, comparable to the overlap seen for macroH2A1
and XIST RNA (Figure 1A), we observed a 0% frequency
of this class of events.
We also examined the distribution of BRCA1 relative to
the Xi in cells labeled with BrdU or PCNA (Figure S3), as
a recent study indicated that cells showing BRCA1 enrich-
ment near the Xi are in late S phase when the Xi is replicat-
ing (Chadwick and Lane, 2005). However, even cells in late
S phase revealed only a limited spatial relationship be-
tween BRCA1 and the Xi.
These data indicate that BRCA1 does not coat the XIST
RNA-enriched component of the Xi in female somatic
cells. This stands in contrast to the BRCA1 distribution
on the XY chromosomes observed in male pachytene
spermatocytes (Figure 1F), where BRCA1 localizes along
the entire surface of unsynapsed XY chromosome axes
(Turner et al., 2004). This difference may reflect the find-
ing that meiotic XY silencing proceeds by a mechanism
involving silencing of unsynapsed DNA (Turner et al.,
2006), which is distinct from X chromosome inactivation
in somatic cells.
Analysis of XIST RNA in a BRCA1-Deficient Cell Line
Analysis of BRCA1-deficient cells suggested a role for this
tumor-suppressor protein in localization of XIST RNA to
the Xi (Ganesan et al., 2002). The BRCA1-deficient
HCC1937 human female breast cancer cell line contains
a nonsense BRCA1 mutation that results in production
of a truncated, unstable protein (Scully et al., 1999; Tom-
linson et al., 1998). Although HCC1937 cells were shown
to express near wild-type levels of XIST RNA, they lacked
the appearance of an X chromosome coated by the XIST
RNA, as well as other features of Xi heterochromatin
(Ganesan et al., 2002). Reconstitution of wild-type BRCA1
in this line was reported to restore XIST staining without
Figure 1. Localization of BRCA1 Relative
to the Xi
(A) The human female fibroblast cell line WI-38
was stained for the histone variant macroH2A
and XIST RNA, which both showed specific
enrichment on the Xi.
(B–D) Three distributions of BRCA1 relative to
the XIST RNA in WI-38 cells. WI-38 cells were
stained by immunofluorescence for BRCA1
and FISH for XIST RNA; the frequency of each
BRCA1 localization pattern is shown as an inset
for each merged image.
(E) Magnification showing the slight degree of
overlap between XIST RNA and BRCA1 signals
from the merged image in (D).
(F) BRCA1 and g-H2AX staining in mouse
pachytene spermatocytes.affecting the steady-state levels of XIST RNA (Ganesan
et al., 2002).
First, we analyzed XIST RNA localization in two different
samples of parental HCC1937 cells obtained indepen-
dently from American Type Culture Collection (ATCC).
Three patterns of XIST RNA localization were observed:
no detectable XIST RNA, a pinpoint XIST RNA signal,
and XIST RNA accumulations that were smaller and
more dispersed than those seen in wild-type fibroblasts
(Figures 2A and 2B). Both samples differed in the propor-
tion of cells exhibiting each pattern (Figure 2D). These re-
sults indicate that there is considerable variability in the
distribution of XIST RNA among the vials of commercially
available HCC1937 cells, which complicates analysis of
cell lines derived from HCC1937 cells.
Next, we compared the distribution of XISTRNA in inde-
pendently obtained pairs of HCC1937 cell lines carryingeither wild-typeBRCA1 in a retroviral vector or empty vec-
tor (Figure S4; Scully et al., 1999; Zhang et al., 2004). In all
four lines, cells exhibited either a pinpoint of XIST RNA or
no detectable XIST RNA (Figure 2C). The different
HCC1937+BRCA1WT and HCC1937+vector cell lines
showed comparable proportions of cells exhibiting XIST
RNApinpoints regardless ofBRCA1 genotypic status (Fig-
ure 2D). A wild-type XIST RNA localization pattern was
never observed in HCC1937+BRCA1WT or HCC1937+
vector cell lines.
Reconstitution of Brca1WT in mouse Brca1 mutant
mammary tumor cell lines also did not change Xist
expression. Full-length murine Brca1 cDNA was trans-
fected into three different Xist RNA-negative cell lines
established from Brca1D11/D11 mouse mammary tumors
(Brca1D11/D11 tumor cell lines 7, 10, and 11 in Table S2;
Brodie et al., 2001). Forty-eight hours after transfection,Cell 128, 977–989, March 9, 2007 ª2007 Elsevier Inc. 979
Figure 2. XIST RNA Localization in
HCC1937 Cells and HCC1937 Cells
Reconstituted with BRCA1
(A) Control XIST RNA-FISH in WI-38 cells.
(B) XIST RNA localization in different aliquots of
HCC1937 cells independently obtained from
ATCC. The XIST localization pattern reflecting
that seen in the majority of cells for each cell
line is shown.
(C) Pinpoint XIST RNA staining in HCC1937+
vector and HCC1937+BRCA1WT lines.
(D) Quantitation of XIST RNA distribution in dif-
ferent samples of HCC1937, HCC1937+vector,
and HCC1937+BRCA1WT lines.
(E and F) Reconstitution of BRCA1-deficient
mouse tumor cells with wild-type BRCA1.
(E) Immunofluorescence staining of BRCA1
and Xist RNA-FISH in Brca1-reconstituted
cells.
(F) BRCA1 protein levels were monitored by
western blot analysis in Brca1D11/D11 cell
populations transfected with either empty
vector or Brca1.
(G) Quantitative RT-PCR analysis was per-
formed on cDNA prepared from the indicated
cell lines using primers specific for XIST and
actin mRNA. XIST RNA levels are expressed
as a ratio to actin mRNA levels after subtraction
of background signal from cDNA synthesis re-
actions lacking reverse transcriptase. To facili-
tate comparison between cell lines of different
genotypes, the ratio of XIST:actin transcripts
was normalized relative to the HCC1937 vec-
tor-reconstituted cell line. Error bars represent
standard deviation.cell populations were analyzed by BRCA1 immunofluo-
rescence and Xist RNA-FISH (green and red, respectively,
in Figure 2E). BRCA1 protein levels in transfected cell
populations were monitored by western blot analysis
(Figure 2F). In 490 BRCA1-positive cells scored among
the three different Brca1D11/D11-transfected cell popula-
tions, none had an Xist RNA signal of any sort. Thus, in
agreement with our analysis of HCC1937 cells, reconsti-
tution of murine BRCA1 in BRCA1-deficient mouse mam-
mary tumor cell lines failed to elicit significant effects on
Xist RNA abundance or localization.
In normal female cells, unspliced XIST transcripts ap-
pear as a pinpoint FISH signal at the XIST locus, in con-
trast to mature, spliced XIST RNA, which coats the Xi
(Clemson et al., 1996). Spliced XIST RNA was not de-
tected in HCC1937+BRCA1WT or HCC1937+vector cells
using quantitative real-time RT-PCR (data not shown). Us-
ing primers that detect spliced and unspliced XIST RNA,
steady-state levels of total XIST RNA were several orders
of magnitude lower in HCC1937+vector and HCC1937+
BRCA1WT cells than in wild-type female fibroblasts
(3600-fold and 700-fold; Figure 2G), consistent with only
nascent XIST transcripts being produced in these
HCC1937 derivative lines. Recently, it was found that980 Cell 128, 977–989, March 9, 2007 ª2007 Elsevier Inc.HCC1937 cells, like many cancer cell lines, show loss of
X chromosome heterozygosity and markers of Xi chroma-
tin, consistent with loss of the Xi (Sirchia et al., 2005).
Therefore, the XIST RNA pinpoint staining observed in
HCC1937 and derivative lines represents low-level, spuri-
ousXIST expression from an Xa.We conclude that BRCA1
reconstitution in HCC1937 cells does not rescue a locali-
zation defect for XIST RNA.
XIST RNA Association with the Xi Persists after
BRCA1 RNA Interference
We examined whether acute knockdown of BRCA1 im-
pacted XIST localization in cells containing a bona fide
XIST-expressing Xi. Lentiviral infection was used to trans-
duce telomerase-immortalized human mammary epithe-
lial cells (HMEC-t) with either empty vector or a plasmid
expressing a shRNA to BRCA1. While an average of
62%of HMEC-t cells stably transfected with empty vector
exhibited positive staining for BRCA1, only 7% of HMEC-t
cells stably expressing the BRCA1 shRNA stained positive
for BRCA1, indicating significant depletion of BRCA1 in
most cells (Figures 3A and 3B). Western blot analysis of
both cell populations confirmed that 80% of total
BRCA1 protein levels had been depleted in BRCA1
Figure 3. XIST/Xist RNA Localization after BRCA1 RNA Interference
(A–C) HMEC-t cells stably transfected with either empty vector (A) or a plasmid expressing a shRNA to BRCA1 (B) were analyzed by immunostaining
and RNA-FISH to assess levels of BRCA1 and XIST RNA. Western blot analysis showed an 80% depletion of BRCA1 protein levels relative to cyclo-
philin B after RNAi in HMEC-t and HEK293 cells (C).
(D–I) Similar analyseswere performed in HEK293 cells eithermock transfected or transfectedwith a pool of siRNAs for BRCA1 (D and E) and inMMTV-
Neu transgenic mouse mammary cancer cells (NK cells) mock transfected or transfected with BRCA1 shRNAs (G and H). Western analysis indicated
80% depletion of BRCA1 relative to cyclophilin B in HEK293 cells (F) and 85% depletion of BRCA1 relative to actin in NK cells (I).shRNA-expressing cells relative to control cell popula-
tions (Figure 3C). XIST RNA staining in BRCA1 shRNA-
transfected cells was indistinguishable from that observed
for vector-transfected cells, with an average of 91% and
92% of cells showing normal XIST RNA localization,respectively (Figures 3A and 3B). Similar results were ob-
tained when HEK293 cells were reiteratively transfected
with a pool of siRNAs specific to BRCA1 (80% depletion;
Figures 3D–3F),whenMMTV-Neu transgenicmousemam-
mary tumor cells (NK) were transfected with a shRNACell 128, 977–989, March 9, 2007 ª2007 Elsevier Inc. 981
Figure 4. X Chromosome DNA-FISH and
Xist RNA-FISH for Mouse Brca1 Mutant
Cell Lines and PrimaryMammary Tumors
Total X chromosome number or signals and
Xist RNA signals for two primary mammary tu-
mors, 1570 (A) and 2579 (B), and twomammary
tumor cell lines,W0069 (C) andW780 (D). Chro-
mosome spreads were hybridized with either
SpectrumOrange-labeled flow-sorted mouse
X chromosome (left and middle panels) or
SpectrumGreen- or SpectrumOrange-labeled
mouse Xist probe (right panel). Signals for Xist
RNA or the X chromosome were pseudocol-
ored to green; DAPI-stained DNA is shown in
red. Both 1570 andW0069 contain multiple ac-
cumulations of Xist RNA. Sample 2579 has
about 22% Xist RNA-positive cells, and W780
lacks Xist RNA signal.specific for BRCA1 (85% depletion; Figures 3G–3I), and in
IMR-90 cells (Figure S5). Therefore, the XIST/Xist tran-
script remains abundant and can coat the Xi despite sig-
nificant depletion of BRCA1.
Xist RNA Accumulates on the Xi in Murine Brca1
Mutant Tumors
One example of a Brca1 mutation reported to correlate
with Xist RNA mislocalization was the deletion of exon
11: two murine Brca1D11/D11 tumor cell lines completely
lacked detectable Xist RNA (Ganesan et al., 2002). We ex-
amined Xist localization in primary mammary tumors de-
veloped from amouse strain carrying amammary-specific
disruption of Brca1 exon 11 using a Cre-LoxP approach
(Brca1Co/Co;MMTV-Cre; Xu et al., 1999b). We compared
14 Brca1 mutant mammary tumors to 3 Brca1 wild-type
mammary tumors developed fromMMTV-Neu transgenic
mice (Brodie et al., 2001) and found no significant differ-
ence in Xist RNA localization (Figure 4). In 11 of 14 primary
Brca1 mutant mammary tumors and all Brca1 wild-type
tumors, over 90%of cells exhibited normal XistRNA stain-
ing (Figure 4; Figure S6). In many cells, there were multiple
accumulations of Xist RNA, indicating the presence of >2
Xi chromosomes (Figure 4A, right column). Consistent
with this, the primary tumors with two or more Xist foci
in the majority of cells contained three or more X chromo-
somes in most cells (Figure 4A, left and middle columns;
Table S2; data not shown). The Xist RNA-enriched do-
mains in Brca1mutant cells were devoid of H3K4me3 im-982 Cell 128, 977–989, March 9, 2007 ª2007 Elsevier Inc.munofluorescence, indicating that the XistRNA signals we
detected were from an Xi (Figure S7; Boggs et al., 2002).
These data demonstrate that Xist RNA can coat Xi chro-
mosomes in primary Brca1 mutant tumor cells.
Three of the fourteen primary Brca1 mutant tumors ex-
amined showed low frequencies of cells with Xist RNA
(7%, 12%, and 22%; Figure 4B and data not shown).
We examined the number of X chromosomes in two of
these tumors. In the tumor showing 22% of cells with
Xist RNA, most cells (82%) had one X chromosome, sug-
gesting that the lack of Xist RNA staining was due to loss
of the Xi (Figure 4B; sample 3 in Table S2). The other tumor
had 7% of cells with Xist RNA staining and had three or
more X chromosomes in 90% of cells, suggesting that
the Xa was amplified in these cells (sample 2 in Table
S2). This loss and gain of X chromosomes in primary
Brca1mutant tumors is consistent with the general karyo-
typic instability described for Brca1 mutants (Weaver
et al., 2002; Xu et al., 1999a).
Analysis of cell lines derived from Brca1 mutant mam-
mary tumors showed similar variability of Xist RNA stain-
ing, which accompanied losses and gains of X chromo-
somes (Figures 4C and 4D; Table S2). For example, one
cell line had five or more X chromosomes in more than
50% of the cells and four or more Xist RNA bodies in
40% of cells, indicating Xi gain (sample 6 in Table S2).
One line had no detectable Xist RNA staining and a single
X chromosome, indicating loss of the Xi (sample 8 in Table
S2). In another line, 81% of cells had three or more X
Figure 5. XIST RNA Distribution in Hu-
man Breast Cancer Cell Lines
(A) BRCA1 immunostaining in MCF-7 and
L56Br-C1 cells (left and middle panels), and
western blot detection of BRCA1 in HEK293,
MCF-7, and L56Br-C1 cells (right panel).
(B) XISTRNA distribution in fields ofMCF-7 and
L56Br-C1 cells.
(C and D) Quantitation of XIST RNA nuclear
localization patterns in MCF-7 (C) and L56Br-
C1 cells (D).chromosomes without detectable Xist RNA staining, sug-
gesting that the Xa was amplified (sample 7 in Table S2).
Together, our data argue that Xist RNA can properly local-
ize to the Xi in primary Brca1mutant tumors and cell lines.
When loss of Xist RNA staining is observed, it is likely at-
tributable to loss of the Xi, as has been documented for
human cancer cell lines (Kawakami et al., 2004; Sirchia
et al., 2005).
XIST RNA Distribution in Human Breast Cancer
Cell Lines
We also monitored XIST RNA distribution in the human
breast cancer cell lines MCF-7 (BRCA1WT) and L56Br-
C1 (Johannsson et al., 2003). L56Br-C1 cells express
BRCA1Q563Stop, a mutation that truncates over two-thirds
of the C terminus of BRCA1, resulting in an unstable pro-
tein. The absence of BRCA1 in L56Br-C1 was confirmed
by immunostaining and western blotting (Figure 5A). De-
spite the loss of BRCA1 expression in L56Br-C1 cells, nor-
mal XIST RNA accumulations were observed in 61% of
cells (Figures 5B and 5D). Many cells contained two
XIST-enriched nuclear domains, indicating the presence
of multiple Xi chromosomes in these cells. The remaining
39% of L56Br-C1 cells displayed aberrant XIST RNA lo-
calization patterns, ranging from no XIST expression to
dispersed XIST RNA particles. This aberrant XIST RNA lo-
calization could not be attributed to the loss of BRCA1,
since MCF-7 cells showed normal BRCA1 expression
levels and nuclear localization (Figure 5A) and also
showed a similar proportion of cells with aberrant XISTRNA localization patterns (Figures 5B and 5C). Together,
these analyses of human breast cancer cell lines demon-
strate that cells lacking BRCA1 can exhibit normal XIST
RNA localization.
X-Linked Gene Expression in Brca1 Mutant Somatic
Cells and Tumors
Depletion of BRCA1 by RNAi was reported to cause infre-
quent reactivation of an Xi-linked GFP transgene, sug-
gesting that this low-level reactivation may occur through
loss of Xist from the Xi (Ganesan et al., 2002). However,
our data indicated that Xist RNA was normally localized
in cells depleted for BRCA1 by RNAi and in most Brca1
mutant tumors. These results suggest that BRCA1 affects
expression of X-linked genes in a manner independent
of Xist RNA localization. We therefore tested whether
mutation of Brca1 could cause changes in X-linked gene
expression in a strain of Brca1 mutant mice carrying
a germline deletion of full-length Brca1 (Brca1D11/D11).
The mutant mice died during embryonic day (E) 12–18;
however, they could survive to adulthood when a copy
of p53 was also deleted (Brca1D11/D11;p53+/; Xu et al.,
2001).
We analyzed the expression levels of ten X-linked genes
in different embryonic stages by real-time RT-PCR (Fig-
ure 6A). The genes chosen for analysis were broadly dis-
tributed along the X chromosome (Figure S8; Table S3).
Analysis of Brca1D11/D11 and Brca1+/D11 control embryos
revealed no significant alterations in gene expression at
E12, E13.5, E15.5, E16.5, and E18 (Figure 6A and dataCell 128, 977–989, March 9, 2007 ª2007 Elsevier Inc. 983
Figure 6. X-Linked Gene Expression Analysis in Somatic Cells and Mammary Tumors of Brca1 Mutant Mice
(A) RNA expression levels of ten X-linked genes. A representative result of embryonic stage E13.5 is shown for one Brca1D11/D11 mutant compared
with its Brca1+/D11 heterozygote littermate. Error bars in (A) and (B) represent standard deviation.
(B) Mammary tumor tissue from a Brca1D11/D11 mutant mouse was compared with normal mammary gland tissue from the same mouse. A >2-fold
increase in expression levels of Vbp1, Ddx3x, and Ube1x in the tumor tissue was observed.
(C and D) Xist RNA-FISH and X chromosome paint (green) and DNA staining (red) in cell lines derived from mammary glands of Brca1mutant (G600)
and wild-type (B477) mice. Representative images of Xist RNA-FISH (C) and X chromosome paint (D) are shown. The Brca1 mutant cell line in (D)
contains X chromosome translocations, while the Brca1WT cell line has normal X chromosomes.
(E and F) Number of X chromosome signals and Xist RNA accumulations in Brca1 mutant (G600; E) and Brca1WT (B477; F) cell lines.not shown). These data indicate that the Brca1D11/D11mu-
tation allows for Xist-dependent initiation of X inactivation.
Next, we compared the expression levels of X-linked
genes in the mammary glands of Brca1D11/D11;p53+/984 Cell 128, 977–989, March 9, 2007 ª2007 Elsevier Inc.mutant and control (p53+/) mice at three different stages
of the mammary cycle: virgin, pregnant day 16.5, and
lactation day 1. Again, we did not observe any significant
alterations in the expression levels of the same ten
Table 1. Summary of Cell Lines and Tumor Samples Analyzed for XIST/Xist RNA Localization
Sample or Treatment Brca1/BRCA1 Status Normal Xist/XIST RNA Localization
Sporadic mouse mammary tumors Brca1WT Yes
Brca1 mutant mouse mammary tumors Brca1D11/D11 Yes
Sporadic mouse mammary tumor cell lines Brca1WT Yes
Brca1 mutant mouse mammary tumor cell lines Brca1D11/D11 Yes
HMEC-t BRCA1 RNAi 80% depletion of BRCA1 Yes
HEK293 BRCA1 RNAi 80% depletion of BRCA1 Yes
NK BRCA1 RNAi 85% depletion of BRCA1 Yes
MCF-7 BRCA1WT Yes
L56Br-C1 BRCA11806C>T (BRCA1Q563Stop) YesX-linked genes analyzed in Figure 6A (data not shown).
Using a cDNA microarray containing 690 X-linked genes
that are expressed at these three stages of the mammary
cycle of development, we found that 16 X-linked genes
showed altered expression levels in Brca1D11/D11;p53+/
mammary glands in comparison with controls at all three
time points (Table S4). Among these 16 genes, 9 were up-
regulated and 7 were downregulated. These results indi-
cate that mutation of Brca1 could affect expression of
a few X-linked genes in mammary tissues. However, it is
unlikely that this was caused by failure of X chromosome
inactivation, as seven of the genes were downregulated
and Xist RNA was expressed in all of the Brca1 mutant
mammary tissues. Consistent with this, a cell line derived
from Brca1D11/D11;p53+/ mammary epithelium exhibited
Xist RNA localization comparable to the p53+/ control
cell line (Figures 6C–6F), indicating that changes in
X-linked gene expression caused by mutation of Brca1
occur in a manner independent of Xist RNA localization.
Finally, X-linked gene expression in six primary mam-
mary tumors developed from Brca1D11/D11;p53+/ mice
were compared with normal mammary tissues obtained
from the same mice using real-time PCR of the same ten
X-linked genes analyzed in Figure 6A. We detected 2- to
76-fold increase in expression of some X-linked genes
(Figure 6B and data not shown), but the genes showing in-
creased expression levels were not consistent among dif-
ferent tumors. Because Brca1 mutant primary tumors ex-
hibit extensive aneuploidy, chromosome rearrangement,
and amplification/loss of X chromosomes (Brodie et al.,
2001; Weaver et al., 2002; Xu et al., 1999a; Figure 4; Table
S2), it is possible that chromosome changes or other
secondary effects of tumorigenesis could cause altered
X-linked gene expression in a manner independent of
Xist RNA.
DISCUSSION
Our studies of BRCA1 and its relationship to XIST RNA
(summarized in Table 1) largely contradict the published
findings of Ganesan et al. (2002). We observed normalXIST/Xist RNA localization when BRCA1 was depleted
by RNAi in human andmouse cells. XistRNA accumulated
properly on the Xi in the majority of Brca1D11/D11 mutant
mouse tumors and in a human BRCA1 mutant breast
tumor line. Brca1D11/D11 mutant embryos had proper X
chromosome dosage compensation, indicating that Xist-
dependent functions during the initiation of X inactivation
were not perturbed. In addition, we did not observe coloc-
alization between BRCA1 and XIST RNA. Although we
cannot account for all of the discrepancies between our
data and the published findings of Ganesan et al., we
feel obligated to report these results.
In their analysis of BRCA1 and XIST RNA colocalization,
Ganesan et al. (2002) stated that, in all instances, colocal-
ization referred to ‘‘costaining of a single, large, discrete
nuclear body.’’ Their accompanying Figure 1 showed ex-
amples of large BRCA1 structures completely overlapping
XISTRNA, a pattern reported to occur in 5%–10%of cells.
In contrast, we were unable to detect convincing colocal-
ization between BRCA1 and XIST RNA. To maximize our
chances of detecting BRCA1/XIST RNA overlap, we
examined the same cell lines that were reported to show
colocalization of BRCA1 with XIST RNA, using the same
antibodies and fixation conditions (Ganesan et al., 2002).
In >5400 total events scored, we could not find one exam-
ple in which BRCA1 and XIST RNA showed significant
overlap (Figure 1; Table S1; Figure S2). Thus, BRCA1 is
not a visibly enriched constituent of XIST-containing chro-
matin on the Xi. Instead, BRCA1 appeared as a small
focus or ‘‘patch’’ next to XIST RNA in a small fraction of
cells (<3%). Whether this denotes a specific relationship
to Xi heterochromatin is unclear: BRCA1 also shows over-
lap with the active X chromosome (Pageau and Lawrence,
2006) and often appears in multiple foci distributed
throughout the nucleus, suggestive of association with
autosomes.
A recent study indicated that when a small focus or
‘‘patch’’ of BRCA1 is in the vicinity of the Xi, the Xi is under-
going replication (Chadwick and Lane, 2005). Cells with
a replicating Xi typically represent 1% of an asynchro-
nous cell population, suggesting that the low frequencyCell 128, 977–989, March 9, 2007 ª2007 Elsevier Inc. 985
of cells showing BRCA1-Xi association that we observed
in human somatic cell typesmay represent cellswith a rep-
licating Xi. When we examined the distribution of BRCA1
relative to the replicating Xi in asynchronous cell popula-
tions, only a subset displayed a limited spatial relationship
between BRCA1 and the replicating Xi (Figure S3). In com-
bination, our localization data indicate that BRCA1 may
associate with a component of the replicating Xi that is
not coated by XISTRNA, in amanner thatmay be stochas-
tic or extremely transient in a given cell population. Be-
cause our data do not indicate a role for the infrequent
BRCA1-Xi association in regulating XIST RNA, the func-
tional relevance of this BRCA1 localization pattern re-
mains an unresolved question.
It was previously argued that the HCC1937 BRCA1-
deficient tumor cell line harbored a defect in XIST RNA
localization that was attributable to mutant BRCA1 geno-
typic status (Ganesan et al., 2002). A more plausible
explanation for this observation is that HCC1937 cells
do not contain an Xi. HCC1937 cells lack Barr bodies,
CpGmethylation of X-linked genes, and histone modifica-
tions that distinguish Xi heterochromatin, indicating that
the X chromosomes present in HCC1937 cells are all tran-
scriptionally active (Ganesan et al., 2002; Sirchia et al.,
2005). Furthermore, the X chromosomes in HCC1937 cells
display extensive homozygosity, which could be attribut-
able to loss of the Xi and amplification of the Xa in tumor
progenitor cells (Sirchia et al., 2005). This phenomenon
also occurs in BRCA1WT tumor cell lines: the T47D,
MDA-MB-231, and HCC2185 breast cancer lines all lack
Barr bodies, XIST expression, CpG methylation of
X-linked genes, and heterozygous X chromosomes
(Sirchia et al., 2005). These BRCA1WT lines all contain
two or more X chromosomes, indicating that the presence
of multiple X chromosomes in any particular cell line or tu-
mor sample is not sufficient evidence for the presence of
an Xi. Several other BRCA1WT cell lines derived from
breast, ovarian, and cervical cancers also lack an Xi
(Huang et al., 2002; Kawakami et al., 2004; Wang et al.,
1990). Thus, the apparent lack of an Xi is common in fe-
male cancer cells and occurs independently of cell type
or BRCA1 genotypic status.
Because there is no evidence for the presence of
inactive X chromosomes in HCC1937 cells, the XIST
RNA in these cells most likely arises from the XIST locus
on an Xa. Previous studies have detected ectopic XIST
RNA transcription from an Xa when cells are treated with
inhibitors of DNA methyltransferases (Hansen, et al.,
1998). Perturbation of DNA methylation in cancer cells
might therefore cause spurious XIST transcription from
an Xa. It is possible that the particular aliquots of
HCC1937, HCC1937+vector, and HCC1937+BRCA1WT
cells analyzed by Ganesan et al. (2002) showed an XIST
RNA localization pattern that suggested a correlation
with BRCA1 expression status. However, we detected
variable patterns of XIST RNA distribution in different cul-
tures of HCC1937 and derivative lines, indicating that dif-
ferences in XIST RNA abundance or localization are likely986 Cell 128, 977–989, March 9, 2007 ª2007 Elsevier Inc.due to stochastic differences in XIST promoter activity
on the Xa.
It was previously reported that XIST/Xist RNA was un-
detectable in BRCA1/Brca1D11/D11 mutant tumor cells
(Ganesan et al., 2002). In contrast, normal XIST/Xist RNA
staining was detected in one BRCA1WT ovarian tumor,
one BRCA1WT breast tumor, and one murine Brca1WT
mammary tumor (Ganesan et al., 2002). However, our
analysis of murine Brca1D11/D11 primary tumors revealed
proper Xist RNA localization in the majority of cells for 11
of 14 tumors. Two Brca1D11/D11 tumor cell lines were re-
ported to have no Xist RNA signal (Ganesan et al., 2002),
but our analysis of six more Brca1D11/D11 tumor cell lines
showed that three of them had normal Xist RNA distribu-
tion. While it is formally possible that other mutations in
Brca1/BRCA1 may exhibit Xist/XIST RNA localization de-
fects (Ganesan et al., 2002), this is unlikely since Xist/XIST
RNA localization also appeared normal upon BRCA1
knockdown and in a human BRCA1 mutant tumor cell
line (Table 1). In addition, normal XIST RNA localization
has recently been reported in a second human BRCA1
mutant tumor cell line (Pageau et al., 2006).
Given the high levels of genomic instability seen in
BRCA1 mutant tumors (Brodie et al., 2001; Tirkkonen
et al., 1997; Tomlinson et al., 1998; Weaver et al., 2002;
Xu et al., 1999a, 1999b), it is likely that tumor samples
with no detectable XIST RNA may simply lack Xi chromo-
somes, which could have been the case in the tumors an-
alyzed by Ganesan et al. (2002). Indeed, we observed ex-
amples of both Brca1D11/D11 primary tumors and cell lines
containing only one X chromosome in the majority of cells.
We also found examples of Brca1D11/D11 primary tumors
and cell lines that had more than one X chromosome but
lacked Xist RNA. These cells are all highly aneuploid, indi-
cating that multiple X chromosomes could have arisen by
an increase in ploidy that resulted in increased numbers of
both the active X chromosome and the Xi, and the subse-
quent loss of the Xi, as has been documented for multiple
BRCA1 mutant and wild-type tumor cell lines (Sirchia
et al., 2005).
A recently published study further weakens any correla-
tion between BRCA1 genotypic status in breast tumors
and the presence of normal XIST RNA association with
the Xi (Richardson et al., 2006). Seventeen of thirty-eight
BRCA1WT basal-like (BLC) and non-BLC tumor samples
lacked detectable XIST RNA staining even though the
BRCA1 was wild-type (Richardson et al., 2006). The dis-
cussion section of Richardson et al. (2006) states that
‘‘One explanation is that, although BRCA1 is intact, BLC
have developed defects in other genes involved in specific
cellular pathways in which BRCA1 also plays a key role,
thus leading to a phenocopy of BRCA1-deficient tumor
cells.’’ However, a more direct explanation for the findings
of Richardson et al. (2006) is that XIST RNA/Xi defects in
breast cancer occur independently of BRCA1 function.
Richardson et al. (2006) also demonstrate a lack of XIST
RNA staining in four human BRCA1/ mutant tumors.
However, all four of these tumors lack markers of Xi
heterochromatin and have lost heterozygosity of the X
chromosome, suggesting loss of the XIST-expressing Xi
in these cells. Twelve of the sporadic, basal-like tumor
samples also showed a loss of heterozygous X chromo-
somes, demonstrating that Xi loss is not unique to
BRCA1/ tumors. The absence of XIST RNA in these
tumors therefore does not indicate a role for BRCA1 in
regulating XIST RNA localization. Instead, the data pre-
sented in Richardson et al. (2006) support the interpreta-
tion that loss of XIST RNA in cancer is often due to loss
of the Xi, as is well documented (Sirchia et al., 2005; Kawa-
kami et al., 2004) and as is supported by our analysis of
murine Brca1 tumors.
Ganesan et al. (2002) reported that depletion of BRCA1
by RNAi caused infrequent reactivation of an Xi-linked
GFP transgene and attributed this low-level reactivation
to loss of Xist RNA. However, we found that Xist RNA
was normally localized in most Brca1 mutant tumors and
cells depleted for BRCA1 by RNAi, suggesting that
BRCA1 may affect expression of X-linked genes in a man-
ner independent of Xist. In Brca1D11/D11 tumor samples,
there were a small number of X-linked genes that were dif-
ferentially expressed when compared to control samples,
yet the identity of the genes varied between different
tumors. Brca1D11/D11 tumors contain variable numbers of
X chromosomes and autosomes, which could cause
changes in X-linked gene expression that would not be di-
rectly attributable to failure of X inactivation or Brca1 mu-
tation. For example, a recent study reported lower levels
of DNA methylation in female embryonic stem cells con-
taining two active X chromosomes when compared with
male embryonic stem cells (Zvetkova, et al., 2005). Alter-
ation of the Xa:autosome ratio in aneuploid cancer cells
could therefore conceivably cause progressive loss of
DNA methylation, leading to gene expression changes
on autosomes as well as X chromosomes.
The X chromosome harbors many genes that are differ-
entially expressed in breast tumors and other types of
cancers (Jazaeri et al., 2002, 2004; Spatz et al., 2004;
Thakur et al., 2005). The question of which of these genes
may contribute to tumor development in BRCA1WT or
BRCA1/ genetic backgrounds remains unresolved.
While changes in expression of X-linked genes may con-
tribute to tumor progression, our data indicate that these
changes are notmediated by perturbation of XIST function
in BRCA1 mutant cells.
EXPERIMENTAL PROCEDURES
Detailed descriptions of all experimental procedures are provided in
the Supplemental Data.
Mice
Brca1Co/Co;p53+/;MMTV-Cre (Xu et al., 1999b), Brca1D11/D11;p53+/
and Brca1D11/+ (Xu et al., 2001), and Brca1D11/D11;Chk2/ (Cao
et al., 2006) mice were generated and genotyped as previously de-
scribed. All animals were handled in accordance with the guidelines
of the NIDDK Animal Care and Users Committee.Antibodies
The antibodies employed were rabbit polyclonal anti-mouse BRCA1
antibody (BRCA1-1059; Turner et al., 2004), rabbit polyclonal antibody
to macroH2A1, mouse monoclonal antibody against g-H2AX (Up-
state), monoclonal antibodies SD118, MS110, and SG11 raised
against human BRCA1, and the GH118 antibody to mouse BRCA1
(Scully et al., 1997a, 1997b; Ganesan et al., 2002).
Total RNA Processing, Microarray Studies, and Real-Time
RT-PCR Analysis
Total RNA was isolated from different stages of embryos, adult mam-
mary glands, or primary mammary tumor tissues using the RNA STAT-
60 (Tel-Test, Inc.). RNA samples were processed by the NIDDK Geno-
mics Core Laboratory at NIH and hybridized with GeneChip Mouse
Genome 430 2.0 (Affymetrix, Inc.). Analysis was performed using Mi-
crosoft Excel. Real-time RT-PCR was carried out using SYBR Green
PCR Master Mix (Applied Biosystems) containing AMV transcriptase
and RNase inhibitors (Roche Applied Science) and a 7500 Real-Time
PCR System (ABI) equipped with SDS software. HCC1937 whole-
cell RNA was isolated using Trizol (Invitrogen). cDNA was synthesized
according to the Superscript II (Invitrogen) protocol. Quantitation was
performed on an MJ Opticon thermal cycler (MJ Research) using
SYBR green to detect PCR products. Primers are listed in Table S3.
Primary Mammary Tumor Samples
Primary mammary tumor samples were cut into small pieces and cul-
tured with 1 mg/ml type 3 collagenase in DMEM with 10% FBS and
EGF and insulin overnight. Cells were then pipetted into a single-cell
suspension, washed twice with medium, and cultured overnight.
One hour before harvesting, cells were treated with 10 ng/ml colcemid.
Chromosome spreads were prepared using methanol:acetic acid (3:1)
fixation. In one instance, cryosections were used for Xist RNA-FISH
analysis.
FISH and Immunofluorescence
Immunostaining was performed as described previously (Ganesan
et al., 2002). FISH, alone or in combination with immunostaining,
was carried out using standard protocols (Panning et al., 1997). Xist/
XIST clones were labeled with SpectrumGreen- or SpectrumOrange-
dUTP (Vysis) or Cy3-dCTP (Amersham). For X chromosome painting,
flow-sorted mouse X chromosomes were labeled by PCR using Spec-
trumOrange-dUTP. Hybridization was performed according to the pro-
tocol listed at http://www.riedlab.nci.nih.gov/protocols.asp.
RNA Interference
RNAi in HMEC-t cells was performed in cells stably transfected with
a shRNA to BRCA1 (Jones et al., 2005). HEK293 cells were transfected
with short RNA duplexes generated from a BRCA1 dsRNA (nucleo-
tides 2000–2580 or 3310–3800) using RNase III. shRNAs specific
for mouse BRCA1 (Open Biosystems, RMM1766-9108401) or pCMS-
EGFP (Clontech) were transfected into mouse mammary cancer
cell line NK (MMTV-Neu transgenic mammary tumor cell line) using
the MEF1 Nucleofector Kit and Nucleofector II machine (Amaxa
Biosystems).
Supplemental Data
Supplemental Data include Supplemental Experimental Procedures,
Supplemental References, four tables, and eight figures and can be
found with this article online at http://www.cell.com/cgi/content/full/
128/5/977/DC1/.
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